Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H De Witte

Showing results (21-30 of 58) with videos related to

Pageof 6
Sort By:
Frontiers in Immunology|September 13, 2017
Inflammatory Conditions Dictate the Effect of Mesenchymal Stem or Stromal Cells on B Cell FunctionFranka Luk, Laura Carreras-Planella, Sander S Korevaar, et al.
Journal of Sport Rehabilitation|October 17, 2017
Improving Mobility Performance in Wheelchair BasketballThom T J Veeger, Annemarie M H de Witte, Monique A M Berger, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 1996
Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshopT J Benraad, J Geurts-Moespot, J Grøndahl-Hansen, et al.
Journal of Sports Sciences|January 17, 2017
Development, construct validity and test-retest reliability of a field-based wheelchair mobility performance test for wheelchair basketballAnnemarie M H de Witte, Marco J M Hoozemans, Monique A M Berger, et al.
British Journal of Cancer|April 3, 1999
Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissueC M Ferrier, H H de Witte, H Straatman, et al.
British Journal of Cancer|July 5, 2001
Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumoursJ H de Witte, J A Foekens, N Brünner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 1998
p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancerE M Berns, J G Klijn, W L van Putten, et al.
Cytotherapy|June 24, 2018
Epigenetic changes in umbilical cord mesenchymal stromal cells upon stimulation and culture expansionSamantha F H De Witte, Fleur S Peters, Ana Merino, et al.
British Journal of Cancer|July 2, 1999
Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancerJ H de Witte, C G Sweep, J G Klijn, et al.
British Journal of Cancer|March 31, 1999
Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patientsJ H de Witte, C G Sweep, J G Klijn, et al.
Pageof 6

Showing results (21-30 of 58) with videos related to

Sort By:
Pageof 6
Frontiers in Immunology|September 13, 2017
Inflammatory Conditions Dictate the Effect of Mesenchymal Stem or Stromal Cells on B Cell FunctionFranka Luk, Laura Carreras-Planella, Sander S Korevaar, et al.
Journal of Sport Rehabilitation|October 17, 2017
Improving Mobility Performance in Wheelchair BasketballThom T J Veeger, Annemarie M H de Witte, Monique A M Berger, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 1996
Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshopT J Benraad, J Geurts-Moespot, J Grøndahl-Hansen, et al.
Journal of Sports Sciences|January 17, 2017
Development, construct validity and test-retest reliability of a field-based wheelchair mobility performance test for wheelchair basketballAnnemarie M H de Witte, Marco J M Hoozemans, Monique A M Berger, et al.
British Journal of Cancer|April 3, 1999
Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissueC M Ferrier, H H de Witte, H Straatman, et al.
British Journal of Cancer|July 5, 2001
Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumoursJ H de Witte, J A Foekens, N Brünner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 1998
p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancerE M Berns, J G Klijn, W L van Putten, et al.
Cytotherapy|June 24, 2018
Epigenetic changes in umbilical cord mesenchymal stromal cells upon stimulation and culture expansionSamantha F H De Witte, Fleur S Peters, Ana Merino, et al.
British Journal of Cancer|July 2, 1999
Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancerJ H de Witte, C G Sweep, J G Klijn, et al.
British Journal of Cancer|March 31, 1999
Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patientsJ H de Witte, C G Sweep, J G Klijn, et al.
Pageof 6